Investing in Mankind Pharma: What You Need to Know

Mankind Pharma Listing: A Stellar Debut

Mankind Pharma made a stellar debut on the stock exchanges on May 9, 2023, listing at a premium of 20.4% over the issue price of Rs. 1,080 per share. The shares opened at Rs. 1,300 apiece on the BSE and NSE, and closed the day at Rs. 1,430, up 32.4%.

The IPO was subscribed 15.32 times, making it the largest issue in a year and the largest by a pharma company after Gland Pharma, which raised Rs. 6,480 crore via IPO in 2020. The high subscription was driven by strong demand from institutional investors, who subscribed 49.16 times the shares reserved for them. Retail investors also showed good interest, subscribing 0.92 times the shares reserved for them.

The listing of Mankind Pharma is a positive sign for the Indian pharmaceutical sector, which is currently facing headwinds due to rising input costs and regulatory challenges. The company’s strong track record and its focus on niche therapeutic areas give it good prospects for growth in the future.

Mankind Pharma IPO Details

The Mankind Pharma IPO was open for subscription from April 25 to April 27, 2023. The issue price was fixed at Rs. 1,026-1,080 per share. The company raised Rs. 4,326.36 crore through the IPO, which was used to repay debt and for general corporate purposes.

The IPO was divided into three categories:

• Qualified Institutional Buyers (QIBs): 52%
• Retail Individual Investors (RIIs): 15%
• Non-Institutional Investors (NII): 33%

The shares of Mankind Pharma were listed on the BSE and NSE on May 9, 2023. The stock code for the company is MANKIND.

Mankind Pharma Share Listing Price

The shares of Mankind Pharma listed at a premium of 20.4% over the issue price of Rs. 1,080 per share. The shares opened at Rs. 1,300 apiece on the BSE and NSE, and closed the day at Rs. 1,430, up 32.4%.

The high listing price was due to strong demand from institutional investors. The QIB category was subscribed 49.16 times, while the NRI category was subscribed 3.8 times. Retail investors also showed good interest, subscribing 0.92 times the shares reserved for them.

Mankind Pharma IPO GMP

The grey market premium (GMP) for the Mankind Pharma IPO was around Rs. 110-113 per share in the days leading up to the listing. This means that investors were willing to pay a premium of Rs. 110-113 for the shares over and above the issue price of Rs. 1,080 per share.

The high GMP was an indication that investors were bullish on the prospects of Mankind Pharma. The company has a strong track record and a focus on niche therapeutic areas. These factors are likely to drive the company’s growth in the future.

Mankind Pharma Share Price NSE

The current share price of Mankind Pharma on the NSE is Rs. 1,899.9. This is a significant increase from the issue price of Rs. 1,080 per share. The stock has been on a bull run since its listing, and it is currently trading at a market capitalization of Rs. 41,284.83 crore.

The high share price is a reflection of the strong demand for the company’s shares. Investors are bullish on the prospects of Mankind Pharma, and they believe that the company is well-positioned for growth in the future.

About Mankind Pharma

Mankind Pharma is a leading pharmaceutical company in India. The company was founded in 1995 by Ramesh Juneja and Rajeev Juneja. Mankind Pharma has a strong focus on niche therapeutic areas, such as anti-infectives, dermatology, and pain management. The company also has a presence in the consumer healthcare segment, with brands such as Manforce condoms and Prega News pregnancy test kits.

Mankind Pharma’s Strengths

Mankind Pharma has a number of strengths that make it well-positioned for growth in the future. These strengths include:

• A strong track record: Mankind Pharma has a long and successful track record in the pharmaceutical industry. 
• A focus on niche therapeutic areas: Mankind Pharma’s focus on niche therapeutic areas gives it a competitive advantage. The company is able to generate higher margins in these areas than in more crowded therapeutic areas.
• A strong R&D pipeline: Mankind Pharma has a strong R&D pipeline, which is a key driver of future growth. The company is developing a number of new products, which are expected to launch in the coming years.

Mankind Pharma’s Future Prospects

Mankind Pharma is well-positioned for growth in the future. The company is benefiting from the growth of the Indian pharmaceutical market, which is expected to grow at a CAGR of 10%-12% in the next few years. Mankind Pharma is also benefiting from the increasing focus on niche therapeutic areas, which are growing at a faster pace than the overall pharmaceutical market.

In addition, Mankind Pharma is expanding its international presence. The company has a presence in over 50 countries, and it is looking to expand its presence in emerging markets such as Africa and Latin America.

Overall, Mankind Pharma is a well-managed company with a strong track record. The company is well-positioned for growth in the future, and it is likely to be a major player in the Indian pharmaceutical industry for many years to come.

Investment Considerations

If you are considering investing in Mankind Pharma, there are a few things you should keep in mind. First, the company is a cyclical business, so its performance is likely to be affected by changes in the economic environment. Second, the company is facing increasing competition from both domestic and international players. Third, the company’s valuation is currently high, so you should be prepared for some volatility in the stock price.

Overall, Mankind Pharma is a good investment for investors who are looking for exposure to the Indian pharmaceutical industry. However, you should be aware of the risks involved before investing in the company.

Also Know More from FAQs 

1. When did Mankind Pharma IPO list?

A: Mankind Pharma IPO listed on May 9, 2023.

2. What was the issue price of Mankind Pharma IPO?

A: The issue price of Mankind Pharma IPO was Rs. 1,026-1,080 per share.

3: What was the subscription status of Mankind Pharma IPO?

A: Mankind Pharma IPO was subscribed 15.32 times.

4: What is the current share price of Mankind Pharma?

A: The current share price of Mankind Pharma on the NSE is Rs. 1,899.9.

5: What are the strengths of Mankind Pharma?

A: Mankind Pharma has a number of strengths, including a strong track record, a focus on niche therapeutic areas, and a strong R&D pipeline.

6: What are the future prospects of Mankind Pharma?

A: Mankind Pharma is well-positioned for growth in the future. The company is benefiting from the growth of the Indian pharmaceutical market and is expanding its international presence.

7: What are the investment considerations for Mankind Pharma?

A: If you are considering investing in Mankind Pharma, you should be aware of the risks involved, such as the cyclical nature of the business and the increasing competition.